Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab
Authors:
- A. KuekAKA. Kuek
- B. L. HazlemanBHB. L. Hazleman
- J. H. GastonJGJ. H. Gaston
- A. J. K. ÖstörAÖA. J. K. Östör
- 18 August 2006
- journal article
- case report
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 45 (11) , 1448-1449
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- B lymphocytes on the front line of autoimmunityAutoimmunity Reviews, 2006
- The use of anakinra in juvenile arthritisCurrent Rheumatology Reports, 2005
- Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvementArthritis Research & Therapy, 2005
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label studyAnnals of the Rheumatic Diseases, 2003
- Long‐term outcome in patients with juvenile idiopathic arthritisArthritis & Rheumatism, 2002
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000
- 2 EpidemiologyBailliere's Clinical Rheumatology, 1998